Setback for pharmaceutical companies in the Zantac case

A Delaware judge has ruled in favour of allowing expert witnesses to testify in a case involving the now-cancelled drug Zantac and its potential carcinogenicity.

Samuel Lagercrantz: “Companies that do this successfully will take the lead”

The development of new medicines and medical technologies should not focus too narrowly on prolonging life. It is equally important to develop treatments that r...

EMA review confirms a risk of new cancer after CAR-T

CAR-T cancer therapies can, in rare cases, induce secondary cancers. The European Medicines Agency (EMA) now recognises this and requires a warning label to be ...

Lillys fetmaläkemedel godkänns mot sömnapné i USA – men inte i EU

Viktminskningsläkemedlet Zepbound (tirzepatid) godkänns av den amerikanska läkemedelsmyndigheten FDA som den första läkemedelsbehandlingen för måttlig till svår...

Learn from Speakers from Leading MedTech Companies

Watch the recordings from ZEISS Quality Innovation Days whenever it suits you.

HAB Nicolai Johannsen

Tungt namn föreslås ta över klubban i Sobi

Valberedningen i särläkemedelsbolaget Sobi föreslår att David Meek utses till ny styrelseordförande vid en extra bolagsstämma i december.

The new ZEISS Celldiscoverer 7 has been launched

Adaptable automation for advanced workflows.

Join us at SLAS Barcelona

Festo LifeTech is exhibiting at the SLAS in Barcelona.

Introduction of ZEISS Imaging Systems for Super-Resolution

Webinar recording about the ZEISS Lattice SIM technology.

Fuskanklagat pharmabolag lägger ner alzheimerprojekt

Amerikanska Cassava Sciences avbryter utvecklingen av sin läkemedelskandidat inom Alzheimers sjukdom efter misslyckande i en fas III-studie

Ancient DNA provides new insights – “The immune system lost its job”

Ancient bone remains from our ancestors have provided new insights into the prevalence of multiple sclerosis. By looking back in time, researchers can provide a...

List: The coolest names in biotech

Hairy beasts, volcanic material and space strolling stand out on a US list of the best biotech company names, and on a list of the coolest names for pharmaceuti...

Eternal Rye – Improving Plant Breeding Methods

User story from Martin Luther University Halle.

Åsa Uppströmer ny vd för Pharma Relations

Pharma Relations har anställt Åsa Uppströmer som ny vd.

KI’s freezer fiasco investigated: A chain of failures

A chain of combined technical and organisational shortcomings caused the freezer breakdown at the Karolinska Institute during the Christmas holidays, destroying...

Storbolag i gräl om hiv-läkemedel

En träta om påstått vilseförande marknadsföring av hiv-läkemedel mellan läkemedelsbolagen Gilead och Glaxo Smith Kline (GSK) har nu avgjorts – till den senares fördel.

Assignment: Facilitate the retention of foreign researchers

A newly appointed public inquiry is to develop measures to make attracting and retaining foreign doctoral students and researchers in Sweden easier.

“What is important is to create an overview and understanding from different perspectives”

Scientist Jochen Schwenk analyses blood proteins using proteomics to improve our understanding of disease and health. This year, he is moderating the Lab & Diag...

Fyra pilotprojekt utvalda i life science-satsning

Bridge Sweden, projektet som går ut på underlätta identifiering och produktion av nya läkemedel, har valt ut sina första projekt.

How Volume EM Advances Life Science Research

Free webinar series.

Hon får tungt uppdrag i Astra Zeneca – ersätter frihetsberövad Kinachef

Astra Zeneca utser Iskra Reic till Executive Vice President (EVP), International. Det betyder att hon får ansvar för bolagets övergripande strategi i stora dela...

”We need compatibility“

Penilla Gunther, founder of Fokus Patient and chair of the European Patient Safety Foundation, hopes that the forthcoming life science strategy will focus on ef...

Recipharm divests five Swedish plants

Swedish contract manufacturer Recipharm is selling its facilities in Solna, Strängnäs, Höganäs, Karlskoga and Uppsala OTC Development to US private equity compa...